1. The name of the medicinal product.U.K.
2. The strength and pharmaceutical form of the product.U.K.
3. Where appropriate, whether the product is intended for babies, children or adults.U.K.
4. Where the product contains up to three active substances, the common name of each active substance.U.K.
5. A statement of the active substances in the product, expressed qualitatively and quantitatively per dosage unit or according to the form of administration for a given volume or weight, using their common names.U.K.
6. The pharmaceutical form and the contents by weight, by volume or by number of doses of the product.U.K.
7. A list of—U.K.
(a)where the product is injectable or is a topical or eye preparation, all excipients; or
(b)in any other case, those excipients known to have a recognized action or effect and included in the guidance [F1published under regulation 257D in the case of products for sale or supply in Great Britain, or in the case of products for sale or supply in Northern Ireland, any guidance published pursuant to Article 65 of the 2001 Directive or under regulation 257D that is applicable to such products.].
Textual Amendments
F1Words in Sch. 24 para. 7(b) substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 201(2) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 155(a)); 2020 c. 1, Sch. 5 para. 1(1)
8. The method of administration of the product and if necessary the route of administration.U.K.
9. Where appropriate, space for the prescribed dose to be indicated.U.K.
10. A warning that the product must be stored out of the reach and sight of children.U.K.
11. Any special warning applicable to the product.U.K.
12. The product's expiry date (month and year), in clear terms.U.K.
13. Any special storage precautions relating to the product.U.K.
14. Any special precautions relating to the disposal of an unused product or part of a product, or waste derived from the product, and reference to any appropriate collection system in place.U.K.
15. The name and address of the holder of the [F2UK marketing authorisation, EU marketing authorisation] Article 126a authorisation or traditional herbal registration relating to the product and, where applicable, the name of the holder's representative.U.K.
Textual Amendments
F2Words in Sch. 24 para. 15 substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 201(3) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 155(b)); 2020 c. 1, Sch. 5 para. 1(1)
16. The number of the [F3UK marketing authorisation, EU marketing authorisation] Article 126a authorisation or traditional herbal registration for placing the medicinal product on the market.U.K.
Textual Amendments
F3Words in Sch. 24 para. 16 substituted (31.12.2020) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019 (S.I. 2019/775), regs. 1, 201(3) (as amended by S.I. 2020/1488, reg. 1, Sch. 2 para. 155(b)); 2020 c. 1, Sch. 5 para. 1(1)
17. The manufacturer's batch number.U.K.
18. In the case of a product that is not a prescription only medicine, instructions for use.U.K.
[F418A. In the case of a medicinal product, other than a radiopharmaceutical, that is required by Article 54a of the 2001 Directive to bear safety features—U.K.
(a)a unique identifier which complies with the technical specifications set out in Chapter II of Commission Regulation 2016/161; and
(b)an anti-tampering device allowing verification of whether the packaging of the medicinal product has been tampered with.]
Textual Amendments
F4Sch. 24 para. 18A inserted (9.2.2019) by The Human Medicines (Amendment) Regulations 2019 (S.I. 2019/62), regs. 1, 19 and Sch. 24 para. 18A inserted (N.I.) (9.2.2019) by The Human Medicines (Amendment) Regulations 2019 (S.R. 2019/10), regs. 1, 19